CX157

From Wikipedia, the free encyclopedia
Jump to: navigation, search
CX157
CX157 structure.svg
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
Formula C14H8F4O4S
Molar mass 348.27 g/mol
3D model (JSmol)
  (verify)

CX157 (proposed trade name TriRima, formerly Tyrima) is a selective and reversible inhibitor of MAO-A (RIMA).[1] As of 2007 it was in phase II clinical trials for the treatment of depression.[2] In 2013, it was discontinued for both depression and anxiety.[1]

References[edit]

  1. ^ Fielding R, Mielach F, Free J, Pande A (2007). Pharmacokinetics and oral bioavailability of CX157, a reversible selective MAO-A inhibitor, in primates (PDF). 2007 AAPS Annual Meeting & Exposition. Retrieved 2009-06-14. 
  2. ^ Clinical trial number NCT00739908 at ClinicalTrials.gov